ECSP15017314A - Formulacion de anticuerpos - Google Patents
Formulacion de anticuerposInfo
- Publication number
- ECSP15017314A ECSP15017314A ECIEPI201517314A ECPI201517314A ECSP15017314A EC SP15017314 A ECSP15017314 A EC SP15017314A EC IEPI201517314 A ECIEPI201517314 A EC IEPI201517314A EC PI201517314 A ECPI201517314 A EC PI201517314A EC SP15017314 A ECSP15017314 A EC SP15017314A
- Authority
- EC
- Ecuador
- Prior art keywords
- cells
- baffr
- antibody
- survival
- baff
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El par BAFFR:BAFF está profundamente involucrado en la maduración de las células B de transición, para la supervivencia y la activación de las células B maduras, y para la conmutación de clase de isotipo en respuesta a antígenos dependientes de células T. BAFF y su receptor BAFFR también son importantes para la supervivencia y el crecimiento de células B malignas. Además, BAFFR normalmente no se expresa en células pre-B, pero 10 recientemente se mostró expresado en células humana de ALL (leucemia linfoblástica aguda de linaje B) (Parameswaran, 2010, Cancer Res. 70(11) 4346-4356). La eliminación de las células B auto-reactivas y el bloqueo de supervivencia/activación no apropiadas mediadas por los niveles BAFF de exceso en pacientes que sufren de trastornos autoinmunes o cáncer representa un objetivo terapéutico bien validado. Por lo tanto, un anticuerpo anti-BAFFR, en 15 particular, un anticuerpo capaz de citotoxicidad mediada por células dependiente de anticuerpos (ADCC) y el bloqueo de la unión del ligando a BAFFR puede constituir un agente terapéutico eficaz en las enfermedades autoinmunes y neoplasias de células B. Los anticuerpos contra BAFFR se conocen a partir de, por ejemplo, el documento WO 2010/007082 e incluyen anticuerpos que se caracterizan por que comprenden un dominio VH 20 con la secuencia de aminoácidos de la SEC ID No: 1 y un dominio VL con la secuencia de aminoácidos de SEQ ID NO: 2. El anticuerpo MOR6654 es uno de estos anticuerpos (IgG1 kappa). Éste tiene
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658472P | 2012-06-12 | 2012-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15017314A true ECSP15017314A (es) | 2018-06-30 |
Family
ID=48914378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201517314A ECSP15017314A (es) | 2012-06-12 | 2015-01-12 | Formulacion de anticuerpos |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9216219B2 (es) |
| EP (2) | EP2858671B1 (es) |
| JP (1) | JP6265978B2 (es) |
| KR (1) | KR102124820B1 (es) |
| CN (1) | CN104363920B (es) |
| AR (1) | AR091413A1 (es) |
| AU (1) | AU2013276112B2 (es) |
| BR (1) | BR112014030820B1 (es) |
| CA (1) | CA2875386C (es) |
| CL (1) | CL2014003370A1 (es) |
| CO (1) | CO7151487A2 (es) |
| CY (1) | CY1122181T1 (es) |
| DK (1) | DK2858671T3 (es) |
| EA (1) | EA033373B1 (es) |
| EC (1) | ECSP15017314A (es) |
| ES (1) | ES2751659T3 (es) |
| GT (1) | GT201400285A (es) |
| HK (1) | HK1203146A1 (es) |
| HR (1) | HRP20191827T1 (es) |
| HU (1) | HUE045523T2 (es) |
| IL (1) | IL235966B (es) |
| LT (1) | LT2858671T (es) |
| MA (1) | MA37616A1 (es) |
| MX (1) | MX363380B (es) |
| MY (1) | MY179818A (es) |
| NZ (1) | NZ630885A (es) |
| PE (1) | PE20150200A1 (es) |
| PH (1) | PH12014502778A1 (es) |
| PL (1) | PL2858671T3 (es) |
| PT (1) | PT2858671T (es) |
| SG (1) | SG11201408174UA (es) |
| SI (1) | SI2858671T1 (es) |
| TN (1) | TN2014000488A1 (es) |
| TW (1) | TWI653983B (es) |
| WO (1) | WO2013186700A1 (es) |
| ZA (1) | ZA201408547B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| KR20160127825A (ko) | 2014-03-12 | 2016-11-04 | 프로테나 바이오사이언시즈 리미티드 | 항-mcam 항체 및 관련된 사용 방법 |
| KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| IL305207A (en) * | 2015-03-30 | 2023-10-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema |
| JP2018530540A (ja) * | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用 |
| US11058769B2 (en) * | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| SG11201805123XA (en) * | 2015-12-18 | 2018-07-30 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| BR112018075785A2 (pt) * | 2016-06-16 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | formulação de vacina para o hiv |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| CN110366429A (zh) * | 2017-03-01 | 2019-10-22 | 免疫医疗有限公司 | 单克隆抗体的配制品 |
| AU2018229724A1 (en) * | 2017-03-06 | 2019-10-31 | Merck Patent Gmbh | Aqueous anti-PD-L1 antibody formulation |
| WO2018193471A1 (en) * | 2017-04-18 | 2018-10-25 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
| JP7079844B2 (ja) * | 2017-07-27 | 2022-06-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 高濃度抗ｃ５抗体製剤 |
| CA3073066A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| BR112020010483A2 (pt) * | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| CA3102349A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| JOP20210152A1 (ar) * | 2018-12-18 | 2023-01-30 | Novartis Ag | صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf |
| CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
| JP2022521624A (ja) * | 2019-02-26 | 2022-04-11 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 抗ｃｄ４７抗体を含む製剤、その調製方法および使用 |
| JP2023501781A (ja) | 2019-11-06 | 2023-01-19 | ノバルティス アーゲー | シェーグレン症候群の処置 |
| WO2021136274A1 (zh) * | 2019-12-30 | 2021-07-08 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| CA3168600A1 (en) * | 2020-01-21 | 2021-07-29 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
| IL300086A (en) | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of B-cell malignancies |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| CN117203240A (zh) | 2021-05-04 | 2023-12-08 | 诺华股份有限公司 | 使用抗baffr抗体治疗狼疮肾炎 |
| EP4334351A1 (en) | 2021-05-04 | 2024-03-13 | Novartis AG | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
| TW202330604A (zh) * | 2021-09-29 | 2023-08-01 | 美商蜻蜓醫療公司 | 靶向ｂａｆｆ—ｒ的抗體及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| WO2000078930A1 (en) | 1999-06-23 | 2000-12-28 | Oregon Health Sciences University | Method for enhancing hematopoiesis |
| WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| EP3210624A1 (en) | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| DK2315780T3 (en) * | 2008-07-17 | 2015-10-19 | Novartis Ag | Compositions and methods for the use of therapeutic antibodies |
| CN102665691B (zh) * | 2009-11-17 | 2015-05-27 | 益普生制药股份有限公司 | hGH和rhIGF-1组合的制剂 |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active IP Right Grant
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en active Application Filing
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-04-15 HK HK15103657.1A patent/HK1203146A1/xx unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-09 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15017314A (es) | Formulacion de anticuerpos | |
| JP2017528462A5 (es) | ||
| MX2016005666A (es) | Anticuerpos anti-cd38 especificos para tratar canceres humanos. | |
| CY1122165T1 (el) | Αντισωματα anti-cd38 | |
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| ECSP20020111A (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| JP2017507954A5 (es) | ||
| PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| AU2011262758A8 (en) | Anti-tim-3 antibody | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR050036A1 (es) | Anticuerpos anti - igf- ir y sus usos | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| UA117294C2 (uk) | Імунокон'югат | |
| PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
| MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
| MX2021004732A (es) | Anticuerpos de cadena pesada que se unen a cd38. | |
| RU2016121105A (ru) | Антитело к gd2-o-ацетилированному ганглиозиду с проапоптозной активностью |